Ozempic is a prescription medication made by Novo Nordisk and primarily used to treat patients with type 2 diabetes.

People using GLP-1 drugs like Ozempic are reporting "Ozempic teeth," an unusual side effect impacting dental health. "Ozempic teeth" may involve tooth decay, sensitivity, and tooth loss. Dentists ...

Ozempic may be adding some spring to your step — but it might also be taking a bite out of your smile. As the popularity of weight-loss drugs surges, a new concern is emerging: “Ozempic teeth ...

New research has shown that Ozempic can cause taste changes in people taking it, even going so far as to make some hate the taste of meat. Click to Skip Ad Closing in ...

Drugs like Ozempic and other GLP-1 agonists mimic this hormone. In a recent study , increasing levels of Bacteroides vulgatus in diabetic mice led to more GLP-1 production. But the benefits didn ...

You may have heard of "Ozempic face" and "Ozempic butt." Well, now there's "Ozempic mouth" and "Ozempic feet" to describe more effects of GLP-1 receptor agonists. Newsletters Games Share a News Tip ...

Hollywood celebrities using popular weight loss drug Ozempic to shred those unwanted pounds are now facing an unexpected new side effect dubbed “Ozempic mouth,” according to a report.

Using Ozempic to lose weight, even when combined with lifestyle changes, is judged as requiring less effort and being less praiseworthy than doing so via dietary changes and exercising.

The research on Ozempic and insulin resistance is encouraging, particularly for individuals struggling with obesity, PCOS, metabolic syndrome, and even neurodegenerative diseases like Alzheimer's.

Monitor lab values regularly while taking Ozempic. Blood tests can identify specific nutritional deficiencies that might contribute to hair loss, allowing for targeted supplementation before hair ...

Ozempic was one of the highest-growth assets on this list—relative to 2023, Ozempic’s sales jumped 26%—and it is poised to see an even greater upward trend in coming years. Originally approved in 2017 ...